Lupin Limited – FDA 483, Jul 11, 2023
Lupin Limited in Nagpur, India, a prescription drug manufacturer, was cited for significant deficiencies in its laboratory controls system. Observations included inadequate security for electronic laboratory data, allowing unauthorized modification and reprocessing of data without justification, and a high number of aborted analytical sequences lacking scientific rationale. Additionally, the firm failed to maintain complete records for samples received for testing, including descriptions, quantities, and receipt dates.
ID · 7d2d92a4-0d81-4760-aa41-a6b025236c26
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.